Gel Documentation Systems Market Size

Gel Documentation Systems Market Analysis

The gel documentation systems market is expected to register a CAGR of 4.1% over the forecast period.

• The gel documentation systems market experienced moderate growth initially when the COVID-19 pandemic began. The high demand for gel documentation systems to analyze protein or nucleic acid bands, including a low-cost and highly sensitive method for detecting SARS-CoV-2, drove this growth. However, the pandemic caused a temporary dip in non-COVID-related research, shifting the focus of the research community, healthcare, and pharma players. As a result, the COVID-19 outbreak moderately impacted the market growth in its preliminary phase. Nonetheless, the market is expected to grow steadily due to increasing research and diagnosis activities for various medical conditions worldwide.
• The prevalence of infectious diseases and genetic disorders and increasing research investments in genomics and proteomics techniques are boosting the growth of the gel documentation systems market. With the growing number of cancer cases worldwide, the demand for gel documentation systems for research applications is expected to increase. For example, according to data published by the Australian Institute of Health and Welfare in June 2022, over 158,530 cases were diagnosed in 2021, and the number of cases of cancer diagnosed increased to 162,163 in Australia in 2022. This increasing prevalence of chronic diseases is expected to drive the growth of the gel documentation system market during the forecast period. Additionally, research collaborations are increasing, which is also expected to boost the demand for gel documentation systems. For example, in February 2023, the University of Texas MD Anderson Cancer Center announced a strategic collaboration with biotech company Xilis to accelerate the development of novel cancer therapies using Xilis' proprietary MicroOrganoSphere (MOS) technology.
• Moreover, in January 2022, Eli Lilly and Company acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology. This acquisition would allow both companies to initiate the research, development, and commercialization of nucleic acid products that target the central and peripheral nervous systems. Eli Lilly will have access to a novel delivery platform technology that can address the challenges of nucleic acid therapeutic modalities, thus contributing to the market's growth. Such developments are expected to increase the demand for research on nucleic acids and proteins, which require gel documentation systems, thus driving the market's growth.
• In conclusion, the gel documentation systems market is anticipated to grow over the analysis period due to the increasing prevalence of diseases and research developments. However, the growing adoption of alternative techniques may impede the market's growth.